Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study

Table 2 Univariate and multivariate analyses of covariates associated with overall survival in patients with metastatic NPC

Variable	Univariate		Multivariate
Variable	HR (95 % CI)	P	HR (95 % CI)	P
Age (<45 years vs. ≥45 years)	1.23 (1.03–1.46)	0.023	1.28 (1.07–1.53)	0.007
Sex (men vs. women)	1.02 (0.81–1.29)	0.870	1.01 (0.79–1.27)	0.958
UICC T category (T1–2 vs. T3–4)	0.91 (0.77–1.09)	0.310	0.94 (0.78–1.12)	0.480
UICC N category (N0–1 vs. N2–3)	1.33 (1.12–1.59)	0.001	1.39 (1.16–1.67)	<0.001
Metastasis onset (synchronous vs. metachronous)	1.13 (0.94–1.37)	0.199	1.24 (1.01–1.53)	0.039
Solitary lesion (no vs. yes)	0.65 (0.50–0.84)	0.001	0.81 (0.61–1.07)	0.140
Lung metastasis (absent vs. present)	0.90 (0.76–1.08)	0.255	1.04 (0.77–1.41)	0.802
Liver metastasis (absent vs. present)	1.39 (1.16–1.67)	<0.001	1.51 (1.13–2.00)	0.005
Bone metastasis (absent vs. present)	1.20 (1.01–1.44)	0.039	1.31 (1.00–1.73)	0.055
Number of involved sites (one vs. two or more)	1.39 (1.16–1.67)	<0.001	0.97 (0.72–1.29)	0.814
Treatment modality (CT vs. CT + LT)	0.67 (0.55–0.82)	<0.001	0.68 (0.55–0.85)	<0.001
BMI		0.001^a		0.003^a
Underweight vs. normal weight	0.84 (0.67–1.04)	0.112	0.90 (0.72–1.12)	0.330
Underweight vs. overweight/obese	0.62 (0.48–0.81)	<0.001	0.64 (0.49–0.84)	0.001

UICC Union of International Cancer Control; CT chemotherapy; LT local therapy; BMI body mass index; HR hazard ratio; CI confidence interval
^a P value with respect to the significance of differential prognosis between BMI subgroups

ISSN: 2523-3548